<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004230</url>
  </required_header>
  <id_info>
    <org_study_id>NU 98CC1</org_study_id>
    <secondary_id>NU-98CC1</secondary_id>
    <secondary_id>NCI-G99-1658</secondary_id>
    <nct_id>NCT00004230</nct_id>
  </id_info>
  <brief_title>Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation</brief_title>
  <official_title>Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell
      transplantation.

      PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the
      side effects in patients who are undergoing bone marrow or stem cell transplantation
      following chemotherapy and radiation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine if captopril can block or prevent lung injury in patients undergoing
      autologous bone marrow or stem cell transplantation following cyclophosphamide and total body
      radiotherapy or high dose chemotherapy. II. Determine a series of surrogate lung injury
      prediction markers for monitoring patients undergoing therapy.

      OUTLINE: This is a randomized study. Patients are stratified according to preparative regimen
      (high dose chemotherapy versus cyclophosphamide and total body radiotherapy). Patients are
      randomized into one of two treatment arms. All patients undergo a conditioning regimen
      consisting of cyclophosphamide daily on days -6 and -5 and total body radiotherapy on day -4
      through -1, or high dose chemotherapy per transplantation protocol. Arm I: Patients receive
      oral captopril 2 to 3 times daily beginning on the first day of the conditioning regimen and
      continuing until day 100 post autologous bone marrow or stem cell transplantation. Arm II:
      Patients receive no captopril while undergoing conditioning therapy. Patients are followed at
      6 months.

      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">March 2002</completion_date>
  <primary_completion_date type="Actual">March 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">35</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>captopril</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Eligible for existing autologous bone marrow or stem cell
        transplantation protocols using either a high dose chemotherapy regimen or a
        cyclophosphamide and total body radiotherapy regimen

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified Other: No other concurrent medical illness that would preclude study

        PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior captopril or other ACE
        inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo I. Gordon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>April 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2004</study_first_posted>
  <disposition_first_submitted>February 16, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 18, 2011</disposition_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary complications</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>testicular embryonal carcinoma</keyword>
  <keyword>testicular choriocarcinoma</keyword>
  <keyword>testicular teratoma</keyword>
  <keyword>testicular yolk sac tumor</keyword>
  <keyword>testicular embryonal carcinoma and teratoma</keyword>
  <keyword>testicular embryonal carcinoma and teratoma with seminoma</keyword>
  <keyword>testicular embryonal carcinoma and yolk sac tumor</keyword>
  <keyword>testicular embryonal carcinoma and yolk sac tumor with seminoma</keyword>
  <keyword>testicular embryonal carcinoma and seminoma</keyword>
  <keyword>testicular yolk sac tumor and teratoma</keyword>
  <keyword>testicular yolk sac tumor and teratoma with seminoma</keyword>
  <keyword>testicular choriocarcinoma and yolk sac tumor</keyword>
  <keyword>testicular choriocarcinoma and embryonal carcinoma</keyword>
  <keyword>testicular choriocarcinoma and teratoma</keyword>
  <keyword>testicular choriocarcinoma and seminoma</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>ovarian yolk sac tumor</keyword>
  <keyword>ovarian embryonal carcinoma</keyword>
  <keyword>ovarian polyembryoma</keyword>
  <keyword>ovarian choriocarcinoma</keyword>
  <keyword>ovarian immature teratoma</keyword>
  <keyword>ovarian mature teratoma</keyword>
  <keyword>ovarian monodermal and highly specialized teratoma</keyword>
  <keyword>ovarian mixed germ cell tumor</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>poor prognosis metastatic gestational trophoblastic tumor</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Captopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

